Table 2.

Posttreatment treatment-related AEs

Clb-Obi
(N = 214)		Ven-Obi
(N = 212)
Total no. of patients with at least 1 AE 10 (4.7%) 17 (8.0%) 
Neutropenia 2 (0.9%) 6 (2.8%) 
Maximum CTC grade 3 1 (0.5%) 3 (1.4%) 
Maximum CTC grade 4 1 (0.5%) 3 (1.4%) 
Febrile neutropenia 1 (0.5%) 2 (0.9%) 
Maximum CTC grade 1 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 1 (0.5%) 1 (0.5%) 
Pneumonia 1 (0.5%) 1 (0.5%) 
Maximum CTC grade 3 1 (0.5%) 1 (0.5%) 
Sepsis 1 (0.5%) 1 (0.5%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 5 0 (0.0%) 1 (0.5%) 
Anemia 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Atrial fibrillation 1 (0.5%) 1 (0.5%) 
Maximum CTC grade 2 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Headache 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Basal cell carcinoma 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 2 1 (0.5%) 0 (0.0%) 
Bladder neoplasm 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Calculus bladder 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Candida infection 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
COVID-19 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Dyspnea 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Hemoptysis 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 2 1 (0.5%) 0 (0.0%) 
Hepatitis viral 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Infected neoplasm 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Infection 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Malignant melanoma 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Ophthalmic herpes zoster 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Penile cancer 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Plasma cell myeloma 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Pneumonia streptococcal 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Pneumonitis 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Prostate cancer 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Sinusitis 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Sinusitis Aspergillus 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Splenomegaly 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Staphylococcal bacteremia 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Streptococcal infection 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
T-cell lymphoma 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Thrombocytopenia 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Toxicity of various agents 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Clb-Obi
(N = 214)		Ven-Obi
(N = 212)
Total no. of patients with at least 1 AE 10 (4.7%) 17 (8.0%) 
Neutropenia 2 (0.9%) 6 (2.8%) 
Maximum CTC grade 3 1 (0.5%) 3 (1.4%) 
Maximum CTC grade 4 1 (0.5%) 3 (1.4%) 
Febrile neutropenia 1 (0.5%) 2 (0.9%) 
Maximum CTC grade 1 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 1 (0.5%) 1 (0.5%) 
Pneumonia 1 (0.5%) 1 (0.5%) 
Maximum CTC grade 3 1 (0.5%) 1 (0.5%) 
Sepsis 1 (0.5%) 1 (0.5%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 5 0 (0.0%) 1 (0.5%) 
Anemia 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Atrial fibrillation 1 (0.5%) 1 (0.5%) 
Maximum CTC grade 2 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Headache 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Basal cell carcinoma 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 2 1 (0.5%) 0 (0.0%) 
Bladder neoplasm 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Calculus bladder 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Candida infection 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
COVID-19 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Dyspnea 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Hemoptysis 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 2 1 (0.5%) 0 (0.0%) 
Hepatitis viral 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Infected neoplasm 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Infection 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Malignant melanoma 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Ophthalmic herpes zoster 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Penile cancer 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Plasma cell myeloma 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Pneumonia streptococcal 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Pneumonitis 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Prostate cancer 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Sinusitis 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Sinusitis Aspergillus 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Splenomegaly 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Staphylococcal bacteremia 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
Streptococcal infection 1 (0.5%) 0 (0.0%) 
Maximum CTC grade 3 1 (0.5%) 0 (0.0%) 
T-cell lymphoma 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 4 0 (0.0%) 1 (0.5%) 
Thrombocytopenia 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 
Toxicity of various agents 0 (0.0%) 1 (0.5%) 
Maximum CTC grade 3 0 (0.0%) 1 (0.5%) 

Investigator-assessed relatedness.

CTC, common terminology criteria.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal